SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Affordability of medicines in the European Union
16 references·0 citing·49 second hop
Affordability of medicines in the European Union (2017)Affordability of medicines in the Europea…Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis (2016)Prices, Costs, and Affordabil…Cost of Illness of Multiple Sclerosis - A Systematic Review (2016)Cost of Illness of Multiple S…Price regulation and parallel imports of pharmaceuticals (2015)Price regulation and parallel…Essential Medicines Are More Available than Other Medicines around the Globe (2014)Essential Medicines Are More …Access to medicines from a health system perspective (2012)Access to medicines from a he…Differences in external price referencing in Europe—A descriptive overview (2011)Differences in external price…Differences in costs of and access to pharmaceutical products in the EU (2011)Differences in costs of and a…Cost of disorders of the brain in Europe 2010 (2011)Cost of disorders of the brai…Consumers' views on generic medicines: A review of the literature (2009)Consumers' views on generic m…Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Medicine prices, availability…International Prices And Availability Of Pharmaceuticals In 2005 (2008)International Prices And Avai…Costs of disorders of the brain in Europe (2007)Costs of disorders of the bra…Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals (2006)Impact of a generic substitut…What do primary care patients think about generic drugs? (2005)What do primary care patients…Foreign free riders and the high price of US medicines (2005)Foreign free riders and the h…International Differences in Drug Prices (2004)International Differences in …Generic Entry and the Pricing of Pharmaceuticals (1997)Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Pharmaceutical Price Controls and Entry Strategies (2007)Pharmaceutical pricing policies in a global market (2008)Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New Drugs (2013)Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement (2013)Cross-national price differences for pharmaceuticals: how large, and why? (2000)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview (2012)Value in Pharmaceutical Pricing (2013)Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries (2014)Comprehensive Textbook of Psychiatry (1967)Comprehensive Textbook of Psychiatry (1968)The economic cost of brain disorders in Europe (2011)The size and burden of mental disorders and other disorders of the brain in Europe 2010 (2011)Scaling-up treatment of depression and anxiety: a global return on investment analysis (2016)European guideline for the diagnosis and treatment of insomnia (2017)Bulletin of the World Health Organization (2003)Poverty and Access to Health Care in Developing Countries (2008)Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration (2013)Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries (2016)How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries (2017)Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data (2010)Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries (2011)Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and Health Action International methodology (2019)Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability (2020)Selection and Use of Essential Medicines (2023)Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)World Development indicators (2015)A global comparison of the cost of patented cancer drugs in relation to global differences in wealth (2017)Pricing of pharmaceuticals is becoming a major challenge for health systems (2020)International Labour Organization (2022)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. (2009)A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. (2020)Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review (2021)Encouraging the use of generic medicines: implications for transition economies. (2002)Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000 (2005)Patients’ attitudes towards and experiences of generic drug substitution in Norway (2006)Patients’ attitudes towards generic drug substitution in Japan (2010)Demand-side policies to encourage the use of generic medicines: an overview (2013)Potential Clinical and Economic Impact of Switching Branded Medications to Generics (2015)Beliefs about generic drugs among elderly adults in hospital-based primary care practices (2008)Generic and therapeutic substitutions in the UK: are they a good thing? (2010)The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects (2012)THE WORLD MEDICINES SITUATION 2011 (2011)The Economic Costs of Type 2 Diabetes: A Global Systematic Review (2015)Essential medicines for universal health coverage (2016)
this work references cited by second hop

References

  • 2011Cost of disorders of the brain in Europe 20101,720 cited
  • 2008Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis926 cited
  • 2012Access to medicines from a health system perspective351 cited
  • 2016Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis255 cited
  • 2008International Prices And Availability Of Pharmaceuticals In 2005170 cited
  • 2005What do primary care patients think about generic drugs?166 cited
  • 2016Cost of Illness of Multiple Sclerosis - A Systematic Review161 cited
  • 2009Consumers' views on generic medicines: A review of the literature141 cited
  • 2011Differences in external price referencing in Europe—A descriptive overview132 cited
  • 2014Essential Medicines Are More Available than Other Medicines around the Globe126 cited
  • 2011Differences in costs of and access to pharmaceutical products in the EU89 cited
  • 2006Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals85 cited
  • 2004International Differences in Drug Prices72 cited
  • 2005Foreign free riders and the high price of US medicines71 cited
  • 2007

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Costs of disorders of the brain in Europe
67 cited
  • 2015Price regulation and parallel imports of pharmaceuticals65 cited
  • Cited by

    No citing works inside the corpus for this window.